$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000110465913041862 Filed on May 15, 2013

Income Statement

Concept	2013 Q2	2013 Q1	2012 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.450M	$2.500M	$2.020M
YoY Change	83.51%	23.76%
% of Gross Profit
Research & Development	$2.576M	$2.680M	$946.0K
YoY Change	90.67%	183.3%
% of Gross Profit
Depreciation & Amortization	$50.00K	$47.00K
YoY Change	150.0%
% of Gross Profit
Operating Expenses	$6.021M	$5.175M	$2.966M
YoY Change	86.18%	74.48%
Operating Profit	-$6.021M	-$5.175M	-$2.966M
YoY Change	86.18%	74.48%
Interest Expense	$30.00K	$20.00K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$6.000M	-$5.160M	-$2.970M
YoY Change	85.76%	73.74%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.996M	-$5.157M	-$2.966M
YoY Change	85.41%	73.87%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$85.71	-$86.00	-$297.00
COMMON SHARES
Basic Shares Outstanding	18.19M shares	14.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q2	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$54.30M	$59.70M	$38.30M
YoY Change	59.24%	55.87%
Cash & Equivalents	$28.19M	$43.19M	$38.28M
Short-Term Investments	$26.20M	$16.50M
Other Short-Term Assets	$900.0K	$500.0K	$100.0K
YoY Change	350.0%	400.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$55.26M	$60.18M	$38.40M
YoY Change	61.23%	56.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$890.0K	$895.0K	$400.0K
YoY Change	105.07%	123.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$88.00K	$88.00K
YoY Change	-70.67%
Total Long-Term Assets	$978.0K	$983.0K	$400.0K
YoY Change	35.08%	145.75%
TOTAL ASSETS
Total Short-Term Assets	$55.26M	$60.18M	$38.40M
Total Long-Term Assets	$978.0K	$983.0K	$400.0K
Total Assets	$56.24M	$61.17M	$38.80M
YoY Change	60.69%	57.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$216.0K	$948.0K	$1.500M
YoY Change	-64.0%	-36.8%
Accrued Expenses	$1.596M	$1.146M	$1.100M
YoY Change	33.0%	4.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.812M	$2.094M	$2.600M
YoY Change	0.67%	-19.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$15.00K	$11.00K	$100.0K
YoY Change		-89.0%
Total Long-Term Liabilities	$15.00K	$11.00K	$100.0K
YoY Change		-89.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.812M	$2.094M	$2.600M
Total Long-Term Liabilities	$15.00K	$11.00K	$100.0K
Total Liabilities	$1.827M	$2.105M	$2.700M
YoY Change	1.5%	-22.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$27.29M	-$21.29M
YoY Change
Common Stock	$17.00K	$18.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$54.41M	$59.06M	$36.10M
YoY Change
Total Liabilities & Shareholders Equity	$56.24M	$61.17M	$38.80M
YoY Change	60.69%	57.65%

Cashflow Statement

Concept	2013 Q2	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$5.996M	-$5.157M	-$2.966M
YoY Change	85.41%	73.87%
Depreciation, Depletion And Amortization	$50.00K	$47.00K
YoY Change	150.0%
Cash From Operating Activities	-$5.160M	-$4.060M	-$820.0K
YoY Change	31.63%	395.12%
INVESTING ACTIVITIES
Capital Expenditures	$50.00K	$184.0K	$431.0K
YoY Change	66.67%	-57.31%
Acquisitions
YoY Change
Other Investing Activities	-$9.780M	$0.00
YoY Change	10766.67%
Cash From Investing Activities	-$9.840M	-$180.0K	-$430.0K
YoY Change	8100.0%	-58.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$32.70M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	32.65M	34.99M
YoY Change	-100.0%	-6.69%
NET CHANGE
Cash From Operating Activities	-5.160M	-4.060M	-820.0K
Cash From Investing Activities	-9.840M	-180.0K	-430.0K
Cash From Financing Activities	0.000	32.65M	34.99M
Net Change In Cash	-15.00M	28.41M	33.74M
YoY Change	255.45%	-15.8%
FREE CASH FLOW
Cash From Operating Activities	-$5.160M	-$4.060M	-$820.0K
Capital Expenditures	$50.00K	$184.0K	$431.0K
Free Cash Flow	-$5.210M	-$4.244M	-$1.251M
YoY Change	31.9%	239.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	14000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14776000	USD
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	16615000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	574000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	31965000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	756000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	93000	USD
CY2012Q4	us-gaap	Assets Assets	32814000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	875000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1211000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2086000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	2093000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	46847000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16134000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	30721000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32814000	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	88000	USD
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	948000	USD
CY2013Q1	us-gaap	Liabilities Liabilities	2105000	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61167000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	23000000	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16710525	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18191159	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14268068	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12622919	shares
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	946000	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2020000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	2966000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2966000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	259000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	65000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2966000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.14
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43188000	USD
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	28412000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	43188000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4541000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38284000	USD
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1383000	shares
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-2966000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2966000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21290000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5150000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5157000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	-101000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21392000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	5175000	USD
	us-gaap	Operating Expenses OperatingExpenses	21328000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21328000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5175000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1252000	USD
CY2012Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	702000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-818000	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	431000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-431000	USD
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	34992000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	34992000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	33743000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4056000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16772000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-184000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-17824000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	32652000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	77784000	USD
CY2013Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18192318	shares
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13345000	shares
CY2013Q1	ovas	Number Of Principal Stockholders For Which Chief Executive Officer Serves As A General Partner NumberOfPrincipalStockholdersForWhichChiefExecutiveOfficerServesAsAGeneralPartner	1	item
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4943000	shares
CY2013Q1	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	307000	USD
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	370000	USD
CY2013Q1	ovas	Accrued License And Patent Fees Current AccruedLicenseAndPatentFeesCurrent	134000	USD
CY2013Q1	ovas	Accrued Marketing Research And Consulting Liabilities Current AccruedMarketingResearchAndConsultingLiabilitiesCurrent	34000	USD
CY2013Q1	ovas	Accrued Contract Research Organizations Liabilities Current AccruedContractResearchOrganizationsLiabilitiesCurrent	144000	USD
CY2012Q4	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	441000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	471000	USD
CY2012Q4	ovas	Accrued License And Patent Fees Current AccruedLicenseAndPatentFeesCurrent	87000	USD
CY2012Q4	ovas	Accrued Marketing Research And Consulting Liabilities Current AccruedMarketingResearchAndConsultingLiabilitiesCurrent	40000	USD
CY2012Q4	ovas	Accrued Contract Research Organizations Liabilities Current AccruedContractResearchOrganizationsLiabilitiesCurrent	127000	USD
CY2013Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1146000	USD
CY2013Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	141000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	895000	USD
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	481000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21291000	USD
CY2013Q1	ovas	Cash Resources Sufficient To Fund Current Operating Plan CashResourcesSufficientToFundCurrentOperatingPlan	59700000	USD
CY2012Q1	ovas	Common Stock Reverse Stock Split Conversion Ratio CommonStockReverseStockSplitConversionRatio	2.023	pure
CY2013Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Use of estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"> </p> </div>
CY2013Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
CY2013Q1	ovas	Number Of Geographic Segments NumberOfGeographicSegments	1	item
CY2012Q3	ovas	Number Classes Board Of Directors NumberClassesBoardOfDirectors	3	item
CY2012Q3	ovas	Staggered Term Board Of Directors StaggeredTermBoardOfDirectors	P3Y
CY2012Q3	ovas	Percentage Of Capital Stock Holders Whose Affirmative Vote Is Required To Remove Directors PercentageOfCapitalStockHoldersWhoseAffirmativeVoteIsRequiredToRemoveDirectors	0.75	pure
CY2013Q1	us-gaap	Short Term Investments ShortTermInvestments	16515000	USD
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80334000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	837000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-97000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	184000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	140000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	477000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	948000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1033000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	41091000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32652000	USD
CY2013Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	31000	USD
CY2013Q1	ovas	Common Stock Shares Reserved For Potential Conversion Of Stock Options And Awards CommonStockSharesReservedForPotentialConversionOfStockOptionsAndAwards	2663595	shares
CY2012Q4	ovas	Common Stock Shares Reserved For Potential Conversion Of Stock Options And Awards CommonStockSharesReservedForPotentialConversionOfStockOptionsAndAwards	1410461	shares
CY2013Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	8900000	USD
CY2012Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	13300000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2013Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	73000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-61000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	185000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2565000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1158000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	16698000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	93000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	60184000	USD
CY2013Q1	us-gaap	Assets Assets	61167000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2094000	USD
CY2013Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11000	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	59062000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2680000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2495000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-5157000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	37000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21291000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	93000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	36693000	USD
CY2013Q1	ovas	Cash And Money Market Funds Amortized Cost CashAndMoneyMarketFundsAmortizedCost	43188000	USD
CY2013Q1	ovas	Cash And Money Market Funds Fair Value CashAndMoneyMarketFundsFairValue	43188000	USD
CY2013Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	59702000	USD
CY2013Q1	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	4000	USD
CY2013Q1	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	3000	USD
CY2013Q1	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	59703000	USD
CY2012Q4	ovas	Cash And Money Market Funds Amortized Cost CashAndMoneyMarketFundsAmortizedCost	14776000	USD
CY2012Q4	ovas	Cash And Money Market Funds Fair Value CashAndMoneyMarketFundsFairValue	14776000	USD
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	31391000	USD
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	11000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	5000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	31397000	USD

Files In Submission

Name	View Source	Status
0001104659-13-041862-index-headers.html	Edgar Link	pending
0001104659-13-041862-index.html	Edgar Link	pending
0001104659-13-041862.txt	Edgar Link	pending
0001104659-13-041862-xbrl.zip	Edgar Link	pending
a13-7942_110q.htm	Edgar Link	pending
a13-7942_1ex31d1.htm	Edgar Link	pending
a13-7942_1ex31d2.htm	Edgar Link	pending
a13-7942_1ex32d1.htm	Edgar Link	pending
a13-7942_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
ovas-20130331.xml	Edgar Link	completed
ovas-20130331.xsd	Edgar Link	pending
ovas-20130331_cal.xml	Edgar Link	unprocessable
ovas-20130331_def.xml	Edgar Link	unprocessable
ovas-20130331_lab.xml	Edgar Link	unprocessable
ovas-20130331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2013 Q2 Form 10-Q Financial Statement

#000110465913041862 Filed on May 15, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2013 Q2 Form 10-Q Financial Statement

#000110465913041862 Filed on May 15, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst